ArticleJournal of family medicine and primary care2025
Safety, immunogenicity, and breakthrough infections during 1-year follow-up after COVISHIELD™ vaccination among healthcare workers in a teaching institute in North India: A prospective longitudinal study.
Article in Journal of family medicine and primary care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A prospective longitudinal study was planned to assess immunogenicity, safety, and breakthrough infection rates among health care workers (HCWs) after COVISHIELD™ vaccination in a teaching institute in North India. Methods: A total of 518 HCWs were enrolled at baseline for receiving first dose of COVISHIELD™, 429 continued participation for second dose, 415 followed up at 28 days after second dose, 405 at 6 months, and 403 at 1 year from February 2021 to November 2022. At each visit prior, 2 ml of blood sample was collected and plasma separated. Anti-SARS-Cov-2 IgG antibodies against spike protein were detected by Chemiluminescent Immuno-Assay on the VITROS 3600 platform (Ortho-clinical Diagnostics, NJ, USA). Data were analysed for 403 HCWs (completed all follow-ups), using Statistical Package for Social Sciences version 21.0. Results: The mean age of participants was 35.3 years (SD ± 11.11), and males were 50.2%. At baseline (N = 518), proportion of reactive HCWs was 25% (95% CI, 21-29%), which increased significantly to 92% (95% CI, 89-95%) after receiving first dose (N = 403), 95% (95% CI, 92-96%) after second dose (N = 403), and declined to 85% (95% CI, 83-93%) at six months (N = 403). At 1 year, reactivity increased to 89.3% (95% CI, 86-90%; Conclusions: Immunogenicity post-COVISHIELD™ vaccination increased after first and second doses but declined after 6 months and inclined after 1 year of the first dose. The safety profile was within acceptable limits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.